Trial Profile

A phase 2a proof-of-concept study evaluating GSBR-1290 in T2DM and obesity

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aleniglipron (Primary)
Indications Obesity; Type 2 diabetes mellitus
Focus Proof of concept; Therapeutic Use

Most Recent Events

03 Jun 2024 Results presented in the Structure Therapeutics Media Release.
08 Mar 2024 According to a Structure Therapeutics media release, topline data from the obesity cohort is expected latter half of the second quarter 2024.
29 Sep 2023 According to a Structure Therapeutics media release, topline data from type 2 diabetes cohort is expected in latter half of fourth quarter 2023 along with results from the Japanese ethno-bridging study of GSBR-1290. And, the topline data from obesity cohort is expected in the first half 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com